期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

核因子-κB与银屑病的研究进展 被引量：2

下载PDF
导出
摘要 核因子 -κB是一个分布广泛的转录因子 ,可通过调控细胞因子、趋化因子、生长因子、粘附分子等相关基因的表达 ,参与免疫应答、炎症反应、细胞生长及凋亡等生理和 (或 )病理过程。现综述了核因子
作者 聂本勇 郑茂荣 范清源
机构地区 第二军医大学长海医院皮肤科
出处 《国外医学（皮肤性病学分册）》 2003年第2期82-85,共4页 Foreign Medical Sciences(Section of Dermatology and Venereology)
关键词 核因子-ΚB 银屑病 研究进展
分类号 R758.63 [医药卫生—皮肤病学与性病学]
  • 相关文献

参考文献25

  • 1Chen F, Castranova V, Shi X, et al. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem, 1999, 45( 1 ) :7 - 17.
  • 2Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med, 1999, 341 (24) :1817 - 1828.
  • 3Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest, 2001, 107(2): 135 - 142.
  • 4Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest, 2001, 107 ( 1 ) :7 - 11.
  • 5Foo SY, Nolan GP. NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet, 1999, 15 ( 6 ) :229 - 235.
  • 6Rodriguez MS, Thompson J, Hay RT, et al. Nuclear retention of Ikap paBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J Biol Chem, 1999. 274 (13) :9108 -9115.
  • 7Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB ki nase. Science, 1999, 284(5412) :316 - 320.
  • 8Hu Y, Baud V, Oga T, et al. IKKalpha controls formation of the epi dermis independently of NF-kappaB. Nature, 2001, 410(6829) :710 -714.
  • 9Murphy JE, Robert C, Kupper TS. Interleukin - 1 and cutaneous in flammation: a crucial link between innate and acquired immunity. J Invest Dermatol, 2000, 114 ( 3 ) :602 - 608.
  • 10Freedberg IM, Tomic-Canic M, Komine M, et al. Keratins and the ke ratinocyte activation cycle. J Invest Dermatol, 2001, 116 (5) :633 - 640.

同被引文献27

  • 1朱慧婷,王萍,娄卫海,周冬梅,陈维文,蔡念宁.张志礼中西医结合辨治银屑病临床经验[J].北京中医药,2020(8):819-822. 被引量：18
  • 2万霞,李赞华,刘建平.临床研究中的样本量估算:(1)临床试验[J].中医杂志,2007,48(6):504-507. 被引量：62
  • 3[5]Chaudhari U, Romano P, Mulcahy LD,et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised tril[J]. Lancet,2001,357(9271 ): 1842～1847.
  • 4[6]Mease PJ, Goffe BS,Metz J,et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial[J]. Lancet, 2000,356 (9227): 385～390.
  • 5[7]Bachelez H, Flageul B, Dubertret L, et al. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4[J]. J Autoimmun, 1998,11 (1): 53～62.
  • 6[8]Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25(high-affinity interleukin 2 receptor)on Tcells by administration of humanized anti-Tac antibody to patients with psoriasis[J] .J Am Acad Dermatol, 2000,43 (3): 448～458.
  • 7[9]Gottlieb A, Krueger JG, Bright R,et al. Effects of administration of a single dose of a humanized monoclonal antibody to CDlla on the immunobiology and clinical activity of psoriasis[J]. J Am Acad Dermatol, 2000,42(3):428～443.
  • 8[10]Martin A, Gutierrez E, Muglia J, et al. A multicenter doseescalation trial with denileukin diftitox(ONTAK, DAB (389) IL-2) in patients with severe psoriasis[J]. J Am Acad Dermatol,2001,45(6) :871～881.
  • 9[11]Ellis CN, Krunger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes[J]. N Engl J Med, 2001,345(4) :248～255.
  • 10[12]Ogata A, Nishimoto N, Yoshizaki K. Advances in interleukin-6 therapy. Rinsho Byori[J]. 1999,47(4) :321～326.

引证文献2

二级引证文献17

国外医学（皮肤性病学分册）
2003年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部